GLRX2 and breast cancer: To further identify the critical gene involved in BC progression, we performed survival analysis using GLRX2, NMT1, PPP2R2B and TRAF3IP3 based on TCGA datasets, and only low PPP2R2B expression was associated with shorter OS and PFS, suggesting it as an anti-oncogene in BC patients.